Financial News
Latest News about NTLA
Recent news which mentions NTLA
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
February 27, 2022
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 18, 2022
February 18, 2022
From Benzinga
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 14, 2022
February 14, 2022
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 7, 2022
February 07, 2022
From Benzinga
10 Health Care Stocks Whale Activity In Today's Session
February 01, 2022
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2022
January 31, 2022
From Benzinga
A Deep Dive Into the Video Game Industry
January 29, 2022
From Motley Fool
3 Growth ETFs to Consider Buying During This Correction
January 29, 2022
From Motley Fool
5 Charts to Remember if the Stock Market Crashes in 2022
January 19, 2022
From Motley Fool
Is Beam Therapeutics a Good Stock to Buy Now?
January 16, 2022
From Motley Fool
If You Invested $1000 In This Stock 5 Years Ago, Here's How Much You Would Have Today
January 13, 2022
Tickers
NTLA
From Benzinga
"Motley Fool Money" 2022 Investing Preview
January 07, 2022
From Motley Fool
What 4 Analyst Ratings Have To Say About Intellia Therapeutics
January 07, 2022
Tickers
NTLA
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 7, 2022
January 07, 2022
From Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
January 05, 2022
From Benzinga
3 Healthcare Stocks That Could Rocket Higher in 2022
January 04, 2022
From Motley Fool
Better Buy: CRISPR vs. Intellia
January 03, 2022
From Motley Fool
Top 5 Moonshots for 2022 Countdown: My No. 5 Pick
December 22, 2021
From InvestorPlace
3 Healthcare Stocks That Could Double Next Year
December 10, 2021
From Motley Fool
54 Biggest Movers From Yesterday
December 08, 2021
From Benzinga
36 Stocks Moving In Tuesday's Mid-Day Session
December 07, 2021
From Benzinga
Direxion Launches New Nanotechnology ETF, TYNE
November 23, 2021
From ETF Trends
Do CRISPR Therapeutics and Intellia Face a Big Safety Risk?
November 21, 2021
From Motley Fool
From Benzinga
Intellia Therapeutics, Inc (NTLA) Q3 2021 Earnings Call Transcript
November 06, 2021
Tickers
NTLA
From Motley Fool
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
November 04, 2021
From Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
From Benzinga
Biotech Buyouts That Would Be Great for Investors
October 22, 2021
From Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
